Interleukin-2 therapy of human cancer: potential benefits versus toxicity.
Pittsburgh Cancer Institute.
R B
RB
Herberman
D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000276:immunology*; D008213:Lymphocyte Activation; D008222:Lymphokines / Q000627:therapeutic use; D009369:Neoplasms / Q000628:therapy*
D007376:Interleukin-2; D008222:Lymphokines